What's Happening?
Eli Lilly and Company announced positive results from its Phase 3 ACHIEVE-4 trial, which evaluated the efficacy and safety of Foundayo (orforglipron) in adults with type 2 diabetes and obesity or overweight
at increased cardiovascular risk. The study, which is the largest and longest of its kind for Foundayo, involved over 2,700 participants across 15 countries. Foundayo demonstrated a non-inferior risk of major adverse cardiovascular events (MACE-4) compared to insulin glargine, with a 16% lower risk of such events. Additionally, Foundayo showed superior improvements in A1C levels and body weight over 52 weeks, which persisted through 104 weeks of therapy. The trial also indicated a 57% lower risk of all-cause death for Foundayo compared to insulin glargine. These findings support the cardiovascular safety and potential health benefits of Foundayo for patients with elevated cardiovascular risk.
Why It's Important?
The results of the ACHIEVE-4 trial are significant as they suggest that Foundayo could become a vital treatment option for individuals with type 2 diabetes, particularly those with obesity or overweight and increased cardiovascular risk. The demonstrated cardiovascular safety and efficacy in reducing A1C levels and body weight could lead to improved health outcomes for these patients. The potential for a once-daily oral medication without food or water restrictions offers a convenient alternative to existing treatments, which could enhance patient adherence and quality of life. The findings also support Eli Lilly's plans to submit Foundayo for regulatory approval by the U.S. Food and Drug Administration, potentially expanding treatment options for millions of Americans affected by type 2 diabetes.
What's Next?
Eli Lilly plans to submit Foundayo for the treatment of type 2 diabetes to the U.S. FDA by the end of the second quarter. If approved, Foundayo could become a new standard of care for managing type 2 diabetes, particularly for patients with additional cardiovascular risks. The company will likely continue to monitor the long-term effects of Foundayo and explore its potential applications in other conditions such as obstructive sleep apnea and osteoarthritis knee pain. The pharmaceutical industry and healthcare providers will be closely watching the FDA's decision, as it could influence treatment protocols and patient management strategies.
